vs
Ginkgo Bioworks Holdings, Inc.（DNA）与SOUTHERN FIRST BANCSHARES INC（SFST）财务数据对比。点击上方公司名可切换其他公司
Ginkgo Bioworks Holdings, Inc.的季度营收约是SOUTHERN FIRST BANCSHARES INC的1.0倍（$33.4M vs $31.8M），SOUTHERN FIRST BANCSHARES INC同比增速更快（26.1% vs -23.8%），SOUTHERN FIRST BANCSHARES INC自由现金流更多（$29.9M vs $-47.7M），过去两年SOUTHERN FIRST BANCSHARES INC的营收复合增速更高（22.2% vs -6.2%）
Ginkgo Bioworks Holdings, Inc.是一家2008年由五名麻省理工学院科学家创立的美国生物技术企业，由杰森·凯利掌舵。公司专注于基因工程改造，为其他生物科技企业开发具备工业应用价值的菌株，帮助合作方省去合成生物学设计初期的重复研发成本，号称「生物制造平台企业」，2019年估值就已达42亿美元。
第一社区银行股份公司是一家美国银行控股公司，为弗吉尼亚州布卢菲尔德第一社区银行的母公司。截至2012年，该公司旗下银行在弗吉尼亚、西弗吉尼亚和北卡罗来纳共设有45个网点，另有2个网点以人民社区银行名义在田纳西州运营，截至2023年4月，公司总资产达36亿美元。
DNA vs SFST — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $33.4M | $31.8M |
| 净利润 | — | — |
| 毛利率 | — | — |
| 营业利润率 | -211.9% | 40.1% |
| 净利率 | — | — |
| 营收同比 | -23.8% | 26.1% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $-1.41 | $1.19 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $33.4M | $31.8M | ||
| Q3 25 | $38.8M | $31.1M | ||
| Q2 25 | $49.6M | $28.6M | ||
| Q1 25 | $48.3M | $26.5M | ||
| Q4 24 | $43.8M | $25.2M | ||
| Q3 24 | $89.0M | $23.8M | ||
| Q2 24 | $56.2M | $23.1M | ||
| Q1 24 | $37.9M | $21.3M |
| Q4 25 | — | — | ||
| Q3 25 | $-80.8M | $8.7M | ||
| Q2 25 | $-60.3M | $6.6M | ||
| Q1 25 | $-91.0M | $5.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-56.4M | $4.4M | ||
| Q2 24 | $-217.2M | $3.0M | ||
| Q1 24 | $-165.9M | $2.5M |
| Q4 25 | -211.9% | 40.1% | ||
| Q3 25 | -231.8% | 36.4% | ||
| Q2 25 | -132.1% | 30.0% | ||
| Q1 25 | -184.1% | 26.1% | ||
| Q4 24 | -236.3% | 27.3% | ||
| Q3 24 | -62.0% | 24.1% | ||
| Q2 24 | -396.7% | 17.0% | ||
| Q1 24 | -469.1% | 15.9% |
| Q4 25 | — | — | ||
| Q3 25 | -207.9% | 27.8% | ||
| Q2 25 | -121.6% | 23.0% | ||
| Q1 25 | -188.2% | 19.9% | ||
| Q4 24 | — | — | ||
| Q3 24 | -63.3% | 18.4% | ||
| Q2 24 | -386.4% | 13.0% | ||
| Q1 24 | -437.3% | 11.8% |
| Q4 25 | $-1.41 | $1.19 | ||
| Q3 25 | $-1.45 | $1.07 | ||
| Q2 25 | $-1.10 | $0.81 | ||
| Q1 25 | $-1.68 | $0.65 | ||
| Q4 24 | $-1.91 | $0.69 | ||
| Q3 24 | $-1.08 | $0.54 | ||
| Q2 24 | $-4.23 | $0.37 | ||
| Q1 24 | $-3.32 | $0.31 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $422.6M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $508.6M | $368.7M |
| 总资产 | $1.1B | $4.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $422.6M | — | ||
| Q3 25 | $495.5M | — | ||
| Q2 25 | $559.4M | — | ||
| Q1 25 | $325.3M | — | ||
| Q4 24 | $561.6M | — | ||
| Q3 24 | $616.2M | — | ||
| Q2 24 | $730.4M | — | ||
| Q1 24 | $840.4M | — |
| Q4 25 | $508.6M | $368.7M | ||
| Q3 25 | $559.8M | $356.3M | ||
| Q2 25 | $613.0M | $345.5M | ||
| Q1 25 | $647.4M | $337.6M | ||
| Q4 24 | $716.1M | $330.4M | ||
| Q3 24 | $797.9M | $326.5M | ||
| Q2 24 | $833.1M | $318.7M | ||
| Q1 24 | $987.3M | $315.3M |
| Q4 25 | $1.1B | $4.4B | ||
| Q3 25 | $1.2B | $4.4B | ||
| Q2 25 | $1.2B | $4.3B | ||
| Q1 25 | $1.3B | $4.3B | ||
| Q4 24 | $1.4B | $4.1B | ||
| Q3 24 | $1.5B | $4.2B | ||
| Q2 24 | $1.6B | $4.1B | ||
| Q1 24 | $1.6B | $4.1B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-47.7M | $30.5M |
| 自由现金流经营现金流 - 资本支出 | $-47.7M | $29.9M |
| 自由现金流率自由现金流/营收 | -142.8% | 93.8% |
| 资本支出强度资本支出/营收 | 0.0% | 1.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $62.1M |
8季度趋势，按日历期对齐
| Q4 25 | $-47.7M | $30.5M | ||
| Q3 25 | $-31.6M | $14.5M | ||
| Q2 25 | $-40.3M | $10.5M | ||
| Q1 25 | $-51.5M | $7.6M | ||
| Q4 24 | $-42.4M | $25.6M | ||
| Q3 24 | $-103.5M | $26.3M | ||
| Q2 24 | $-84.4M | $4.0M | ||
| Q1 24 | $-89.3M | $-2.9M |
| Q4 25 | $-47.7M | $29.9M | ||
| Q3 25 | — | $14.4M | ||
| Q2 25 | $-40.3M | $10.4M | ||
| Q1 25 | $-59.1M | $7.4M | ||
| Q4 24 | $-56.1M | $24.8M | ||
| Q3 24 | $-118.6M | $26.1M | ||
| Q2 24 | $-111.4M | $3.9M | ||
| Q1 24 | $-96.0M | $-3.2M |
| Q4 25 | -142.8% | 93.8% | ||
| Q3 25 | — | 46.3% | ||
| Q2 25 | -81.2% | 36.3% | ||
| Q1 25 | -122.4% | 28.1% | ||
| Q4 24 | -128.0% | 98.2% | ||
| Q3 24 | -133.2% | 110.0% | ||
| Q2 24 | -198.2% | 16.8% | ||
| Q1 24 | -252.9% | -15.0% |
| Q4 25 | 0.0% | 1.8% | ||
| Q3 25 | 0.0% | 0.3% | ||
| Q2 25 | 0.1% | 0.3% | ||
| Q1 25 | 15.8% | 0.5% | ||
| Q4 24 | 31.3% | 3.1% | ||
| Q3 24 | 16.9% | 0.8% | ||
| Q2 24 | 48.1% | 0.4% | ||
| Q1 24 | 17.7% | 1.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.67× | ||
| Q2 25 | — | 1.59× | ||
| Q1 25 | — | 1.44× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 6.01× | ||
| Q2 24 | — | 1.32× | ||
| Q1 24 | — | -1.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DNA
| Cell Engineering Segment | $26.0M | 78% |
| Other | $7.4M | 22% |
SFST
暂无分部数据
